MSH2 Loss in Primary Prostate Cancer

PURPOSE: Inactivation of mismatch repair (MMR) genes may predict sensitivity to immunotherapy in metastatic prostate cancers. We studied primary prostate tumors with MMR defects. EXPERIMENTAL DESIGN: 1133 primary prostatic adenocarcinomas and 43 prostatic small cell carcinomas (NEPC) were screened b...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin Cancer Res
Asıl Yazarlar: Guedes, Liana B., Antonarakis, Emmanuel S., Schweizer, Michael T., Mirkheshti, Nooshin, Almutairi, Fawaz, Park, Jong Chul, Glavaris, Stephanie, Hicks, Jessica, Eisenberger, Mario A., De Marzo, Angelo M., Epstein, Jonathan I., Isaacs, William B., Eshleman, James R., Pritchard, Colin C., Lotan, Tamara L.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2017
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5690834/
https://ncbi.nlm.nih.gov/pubmed/28790115
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-0955
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller